Fig. 1.

Analytic framework. a Decision analytic framework. In each annual cycle, a patient may transition to another health state due to recurrence or death. The level of 3-year recurrence risk is based on each patient’s 12-gene assay result. b Health state transitions. Transitions between health states may occur in the direction of the arrows. Transition probabilities based on data from the QUASAR randomized clinical trial and clinical validation study and whether or not the patient chose to undergo adjuvant chemotherapy (with usual care or also having available 12-gene assay results). FOLFOX 5-fluorouracil and leucovorin, and oxaliplatin, QUASAR Quick and Simple and Reliable